Real-time tumor-tracking radiotherapy with SyncTraX for primary liver tumors requiring isocenter shift†.

ABSTRACT: The SyncTraX series enables real-time tumor-tracking radiotherapy through the real-time recognition of a fiducial marker using fluoroscopic images. In this system, the isocenter should be located within approximately 5-7.5 cm from the marker, depending on the version, owing to the limited field of view. If the marker is placed away from the tumor, the isocenter should be shifted toward the marker. This study aimed to investigate stereotactic body radiotherapy (SBRT) outcomes of primary liver tumors treated with SyncTraX in cases where the isocenter was shifted marginally or outside the planning target volume (PTV). Twelve patients with 13 liver tumors were included in the analysis. Their isocenter was shifted toward the marker and was placed marginally or outside the PTV. The prescribed do

SUBMITTER: Uchinami Y 

PROVIDER: S-EPMC10803168 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature